Healthcare AI
LillyAI
Transforming an early AI healthcare tool into an enterprise clinical intelligence platform.
Overview
LillyAI began as an AI-assisted clinical report generator that collected evidence from selected medical sources.
ATR Enterprises partnered with Mirai Studios to transform the MVP into a scalable Clinical Intelligence and Health Technology Assessment platform.
Mirai restructured the product around the complete drug-evaluation workflow, including structured clinical intake, multi-source evidence retrieval, AI reasoning, citation validation, economic modelling and human clinical review.
The platform is designed to help pharmaceutical analysts and healthcare stakeholders generate evidence-backed clinical reports, evaluate treatment economics and prepare outputs aligned with international HTA frameworks.
Key capabilities
Multi-source medical evidence ingestion, AI-powered clinical reasoning, citation validation and hallucination controls, HTA-compliant report generation, clinical dosage calculation, economic and budget-impact modelling, human-in-the-loop reviewer workflows, enterprise roles, security and audit trails, and automated report-to-presentation generation.
Outcome
Through product strategy, UX, AI architecture and full-stack engineering, Mirai helped establish the foundation required for LillyAI to evolve from an early MVP into a commercially scalable enterprise healthcare product.
Mirai Studios helped us transform LillyAI from an early AI reporting product into a structured enterprise platform. Their team brought clarity across product strategy, user experience, AI architecture and development, while working closely with us as a long-term technology partner.
More work
